News | March 16, 2012

Cell>Point, FDA Agree on Phase 3 Trial of Technetium-99m Lung Cancer Imaging Agent

March 15, 2012 - Cell>Point announced that it has received a letter from the U.S. Food and Drug Administration (FDA) indicating agreement on a Special Protocol Assessment (SPA) for Cell>Point’s Phase 3 pivotal clinical study of technetium-99m-EC-G in lung cancer.

The Phase 3 study will assess use of Cell>Point’s molecular imaging product candidate, technetium-99m-EC-G (EthylenediCysteine-n-acetyl-Glucosamine), in the diagnosis and staging of lung cancer.

Study patients receive technetium-99m-EC-G (99mTc-EC-G) intravenously, and a picture, or image, of the cancer area is taken using a Single Photon Emission Computed Tomography (SPECT) camera, commonly referred to as a gamma camera.

“We are extremely pleased to receive agreement from the FDA for this Special Protocol Assessment since it provides us confidence that our study design and statistical analysis plan have the potential to provide results that lead to product approval,” said David Rollo, M.D., Ph.D., president of Cell>Point.

Patients in the study will receive a SPECT scan with 99mTc-EC-G, and a PET scan (Positron Emission Tomography) with fluorine-18 FluoroDeoxyGlucose (18F-FDG). Results will then be independently evaluated, scored and compared for accuracy in diagnosing the presence and location of primary as well as metastatic lesions.

About Special Protocol Assessments

A Special Protocol Assessment is a binding declaration between the trial sponsor and the FDA indicating that the Phase 3 clinical study design, endpoints and statistical analyses are acceptable to support regulatory approval of the product. Final marketing approval depends on study results and an evaluation of benefit/risk profile.

About Technetium-99m-EC-G

Technetium-99m-EC-G is a cancer and cardiovascular diagnostic imaging agent developed for use with SPECT cameras, which are widely available throughout the world. In cancer, Phase 2 clinical trial results showed 100 percent concordance between 99mTc-EC-G and 18F-FDG in non-small cell lung cancer lesion

location, size and confidence that lesions represented cancer. For cardiology, Cell>Point is preparing to start a Phase 2 clinical study to evaluate technetium-99m-EC-G in diagnosing patients with Coronary Artery Disease (CAD). One of the Phase 2 objectives is to compare results of giving technetium-99m-EC-G to patients “at rest” to results of a traditional Myocardial Perfusion Imaging (MPI) “stress and rest” study. (The EC-G rest-only study takes 30 to 45 minutes, whereas a traditional MPI study takes 5 to 7 hours.) Results from the Phase 1b CAD study were very encouraging.

For Technetium-99m-EC-G, the company has completed a Brazil license and a select-country Asia Pacific license.

For more information: www.cellpointweb.com

Related Content

Women With Coronary Artery Wall Thickness at Risk for Heart Disease
News | Cardiac Imaging | April 25, 2019
The thickness of the coronary artery wall as measured by magnetic resonance imaging (MRI) is an independent marker for...
New Study Redefines Therapeutic Dose Guidelines for Non-Small Cell Lung Cancer
News | Lung Cancer | April 23, 2019
Non-small cell lung cancer is a common cancer for both men and women. Many people who are diagnosed with this type of...
Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index

Fig. 1: Comparison of state Medicaid fees for radiation oncology services for breast cancer and nonradiation oncology services per the Kaiser Family Foundation Index. (Agarwal et al, Red Journal, 2019) Credit: Elsevier

News | Radiation Therapy | April 22, 2019
April 22, 2019 — A new study finds wide state
Stereotactic Radiosurgery Effective for Pediatric Arteriovenous Malformation Patients
News | Radiation Therapy | April 19, 2019
Ching-Jen Chen, M.D., of the neurosurgery department at the University of Virginia (UVA) Health System, was the winner...
Video Plus Brochure Helps Patients Make Lung Cancer Scan Decision

Image courtesy of the American Thoracic Society

News | Lung Cancer | April 19, 2019
A short video describing the potential benefits and risks of low-dose computed tomography (CT) screening for lung...
Surgically Guided Brachytherapy Improves Outcomes for Intracranial Neoplasms
News | Brachytherapy Systems | April 18, 2019
Peter Nakaji, M.D., FAANS, general practice neurosurgeon at Barrow Neurological Institute, presented new research on...
Check-Cap Initiates U.S. Pilot Study of C-Scan for Colorectal Cancer Screening
News | Colonoscopy Systems | April 15, 2019
Check-Cap Ltd. has initiated its U.S. pilot study of the C-Scan system for prevention of colorectal cancer through...
Deep Lens Closes Series A Financing for Digital AI Pathology Platform
News | Digital Pathology | April 09, 2019
Digital pathology company Deep Lens Inc. announced the closing of a $14 million Series A financing that will further...
Uterine Fibroid Embolization Safer and as Effective as Surgical Treatment
News | Interventional Radiology | April 05, 2019
Uterine fibroid embolization (UFE) effectively treats uterine fibroids with fewer post-procedure complications compared...
News | Biopsy Systems | March 29, 2019
Dune Medical Devices has just completed the first in-man cases for Smart Biopsy, its percutaneous soft tissue biopsy...